부산대학교 도서관

Yap TA; Popat S

Pharmacogenomics and Personalized Medicine, Vol 2014, Iss default, Pp 285-295 (2014)

Torrado C; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.; Plummer R; Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kigdom.; Yap TA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.; Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX.; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Pilié PG; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Giuliani V; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; McGrail DJ; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.; Bristow CA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Ngoi NYL; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Kyewalabye K; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Wani KM; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Le H; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Campbell E; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sanchez NS; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Yang D; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Gheeya JS; The University of Texas Health Science Center at Houston, Houston, Texas.; Goswamy RV; The University of Texas Health Science Center at Houston, Houston, Texas.; Holla V; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Shaw KR; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Liu CY; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Ma X; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Feng N; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Machado AA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Bardenhagen JP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Vellano CP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Marszalek JR; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Rajendra E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Piscitello D; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Johnson TI; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Likhatcheva M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Elinati E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Majithiya J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Neves J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Grinkevich V; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Ranzani M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Luzarraga MR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Boursier M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Armstrong L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Geo L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Lillo G; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Tse WY; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Kopetz SE; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Geck Do MK; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Lively S; ChemPartner Corporation, San Francisco, California.; Johnson MG; ChemPartner Corporation, San Francisco, California.; Robinson HMR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Smith GCM; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom.; Carroll CL; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Di Francesco ME; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Jones P; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Heffernan TP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Yap TA; University of Texas MD Anderson Cancer Center, Houston, Texas.; Tolcher AW; New Experimental Therapeutics (NEXT), San Antonio, Texas.; Plummer R; Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom.; Mukker JK; EMD Serono, Billerica, Massachusetts.; Enderlin M; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; Hicking C; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; Grombacher T; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; Locatelli G; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; Szucs Z; Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany.; Gounaris I; Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany.; de Bono JS; Royal Marsden Hospital, Sutton, United Kingdom.

Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Maddalena G; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Oncology Unit 1, Veneto Institute of Oncology-IRCCS, Padova; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.; Zeineddine FA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.; Rivero-Hinojosa S; Natera, Inc., Austin.; Aushev VN; Natera, Inc., Austin.; Chowdhury S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.; Zeineddine MA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.; Yousef AM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.; Yap TA; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston; The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston.; EINaggar AC; Natera, Inc., Austin.; Liu MC; Natera, Inc., Austin.; White M; Department of Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.; Overman MJ; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.; Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.; Shen JP; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jshen8@mdanderson.org.

Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Fontana E; Sarah Cannon Research Institute UK, London, UK.; Rosen E; Early Drug Development and Breast Medicine Services, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Lee EK; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Højgaard M; Rigshospitalet, Department of Oncology, Copenhagen, Denmark.; Mettu NB; Medical Oncology, Duke University, Durham, NC, USA.; Lheureux S; Princess Margaret Cancer Centre, Toronto, ON, Canada.; Carneiro BA; Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, Division of Hematology/Oncology, Department of Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA.; Cote GM; Mass General Cancer Center, Boston, MA, USA.; Carter L; Division of Cancer Sciences, The University of Manchester, Manchester, UK.; Christie NHS Foundation Trust, Manchester, UK.; Plummer R; Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne, UK.; Mahalingam D; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Fretland AJ; Repare Therapeutics, Cambridge, MA, USA.; Schonhoft JD; Repare Therapeutics, Cambridge, MA, USA.; Silverman IM; Repare Therapeutics, Cambridge, MA, USA.; Wainszelbaum M; Repare Therapeutics, Cambridge, MA, USA.; Xu Y; Repare Therapeutics, Cambridge, MA, USA.; Ulanet D; Repare Therapeutics, Cambridge, MA, USA.; Koehler M; Repare Therapeutics, Cambridge, MA, USA.; Yap TA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE

Nakazawa MS; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Silverman IM; Repare Therapeutics, Cambridge, Massachusetts, United States.; Rimkunas V; REPARE THERAPEUTICS, Canada.; Veloso A; REPARE THERAPEUTICS, Canada.; Glodzik D; Harvard Medical School, Boston, MA, United States.; Johnson A; REPARE THERAPEUTICS, United States.; Ohsumi TK; REPARE THERAPEUTICS, Cambridge, MA, United States.; Patel SR; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.; Conley AP; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.; Roland CL; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Soliman PT; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.; Beird HC; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Wu CC; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Ingram DR; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Lazcano R; The University of Texas MD Anderson Cancer Center, Houston, United States.; Song D; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Wani KM; The University of Texas MD Anderson Cancer Center, Houston, Tx, United States.; Lazar AJ; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Yap TA; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Wang WL; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Livingston JA; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

Ngoi NYL; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Pilié PG; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; McGrail DJ; Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.; Zimmermann M; Repare Therapeutics, St Laurent, Quebec, Canada.; Schlacher K; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. KSchlacher@mdanderson.org.; Yap TA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.; Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500077 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-4782 (Electronic) Linking ISSN: 17594774 NLM ISO Abbreviation: Nat Rev Clin Oncol Subsets: MEDLINE

Lei G; The University of Texas MD Anderson Cancer Center, HOUSTON, United States.; Mao C; The University of Texas MD Anderson Cancer Center, United States.; Horbath AD; MD Anderson Cancer Center, Houston, Texas, United States.; Yan Y; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.; Cai S; University of Texas MD Anderson Cancer Center, TX.; Yao J; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.; Jiang Y; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Sun M; The University of Texas MD Anderson Cancer Center, HOUSTON, United States.; Liu X; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.; Cheng J; The University of Texas MD Anderson Cancer Center, HOUSTON, United States.; Xu Z; The University of Texas MD Anderson Cancer Center, HOUSTON, United States.; Lee H; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Li Q; The University of Texas MD Anderson Cancer Center, HOUSTON, United States.; Lu Z; The University of Texas MD Anderson Cancer Center, HOUSTON, United States.; Zhuang L; The University of Texas MD Anderson Cancer Center, Houston, United States.; Chen MK; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Alapati A; The University of Texas MD Anderson Cancer Center, HOUSTON, United States.; Yap TA; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Hung MC; China Medical University, Taichung, Taiwan.; You MJ; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Piwnica-Worms H; The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Gan B; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

Rosen E; Early Drug Development and Breast Medicine Services, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Yap TA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Lee EK; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Højgaard M; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.; Mettu NB; Medical Oncology, Duke University, Durham, North Carolina.; Lheureux S; Princess Margaret Cancer Centre, Toronto, Canada.; Carneiro BA; Legorreta Cancer Center at Brown University, and Lifespan Cancer Institute, Division of Hematology/Oncology, Department of Medicine, The Warren Alpert Medical School, Brown University, Providence, Rhode Island.; Plummer R; Newcastle University and Newcastle Hospitals NHS Foundation Trust, Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom.; Fretland AJ; Repare Therapeutics, Cambridge, Massachusetts.; Ulanet D; Repare Therapeutics, Cambridge, Massachusetts.; Xu Y; Repare Therapeutics, Cambridge, Massachusetts.; McDougall R; Repare Therapeutics, Cambridge, Massachusetts.; Koehler M; Repare Therapeutics, Cambridge, Massachusetts.; Fontana E; Sarah Cannon Research Institute UK, London, United Kingdom.

Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE